{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:20:04Z","timestamp":1784204404783,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.10.079","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T03:16:40Z","timestamp":1635995800000},"page":"7429-7440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-4169","authenticated-orcid":false,"given":"Colleen L.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-4324","authenticated-orcid":false,"given":"Helen J.","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-3869","authenticated-orcid":false,"given":"Jane E.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-8664","authenticated-orcid":false,"given":"Samuel J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1050-4574","authenticated-orcid":false,"given":"Michael","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-090X","authenticated-orcid":false,"given":"Anoop K.","family":"Enjeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty R.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Mengersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-0064","authenticated-orcid":false,"given":"John","family":"Litt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.10.079_b0005","unstructured":"University of Oxford. Oxford vaccine reaches one billion doses released. 202https:\/\/www.ox.ac.uk\/news\/2021-07-29-oxford-vaccine-reaches-one-billion-doses-released."},{"issue":"10269","key":"10.1016\/j.vaccine.2021.10.079_b0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"10277","key":"10.1016\/j.vaccine.2021.10.079_b0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"10293","key":"10.1016\/j.vaccine.2021.10.079_b0020","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.10.079_b0025","unstructured":"Vaccine Effectiveness Expert Panel (VEEP) VEEP: Vaccine effectiveness table, 16 July 2021. 2021. https:\/\/www.gov.uk\/government\/publications\/veep-vaccine-effectiveness-table-16-july-2021."},{"key":"10.1016\/j.vaccine.2021.10.079_b0030","unstructured":"Norwegian Institute of Public Health Norwegian Institute of Public Health's recommendation about AstraZeneca vaccine. 2021. https:\/\/www.fhi.no\/en\/news\/2021\/astrazeneca-vaccine-removed-from-coronavirus-immunisation-programme-in-norw\/."},{"key":"10.1016\/j.vaccine.2021.10.079_b0035","unstructured":"Michael Franklin; Timm Bruch Alberta doctors find 2nd case of blood clot linked to AstraZeneca vaccine in Canada. 2021. https:\/\/calgary.ctvnews.ca\/alberta-doctors-find-2nd-case-of-blood-clot-linked-to-astrazeneca-vaccine-in-canada-1.5391531."},{"key":"10.1016\/j.vaccine.2021.10.079_b0040","unstructured":"Medicines & Healthcare products Regulatory Agency, Coronavirus vaccine - weekly summary of Yellow Card reporting. 2021, GOV.UK: United Kingdom."},{"key":"10.1016\/j.vaccine.2021.10.079_b0045","unstructured":"Australian Government Department of Health, COVID-19 vaccine weekly safety report - 12-08-2021, in COVID-19 vaccine weekly safety report. 2021: Australia."},{"issue":"22","key":"10.1016\/j.vaccine.2021.10.079_b0050","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.10.079_b0055","unstructured":"Australian Government Department of Health Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca. 2021. https:\/\/www.health.gov.au\/news\/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca."},{"key":"10.1016\/j.vaccine.2021.10.079_b0060","unstructured":"Australian Government Department of Health ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021. 2021. https:\/\/www.health.gov.au\/news\/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021."},{"issue":"34","key":"10.1016\/j.vaccine.2021.10.079_b0065","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/j.vaccine.2021.07.013","article-title":"Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination \u2013 A risk\u2013benefit analysis for people < 60 years in Australia","volume":"39","author":"MacIntyre","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.079_b0070","doi-asserted-by":"crossref","unstructured":"Nicholas Biddle; Ben Edwards; Matthew Gray; Kate Sollis, Vaccine willingness and concerns in Australia: August 2020 to April 2021. 2021, Australian National University.","DOI":"10.1101\/2021.02.17.21251957"},{"key":"10.1016\/j.vaccine.2021.10.079_b0075","unstructured":"Australian Government Department of Health COVID-19 summary statistics. Coronavirus (COVID-19) case numbers and statistics, 2021. https:\/\/www.health.gov.au\/news\/health-alerts\/novel-coronavirus-2019-ncov-health-alert\/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics."},{"key":"10.1016\/j.vaccine.2021.10.079_b0080","unstructured":"Australian Government Department of Health COVID-19 vaccination \u2013 Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZenec. 2021. https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca."},{"key":"10.1016\/j.vaccine.2021.10.079_b0085","doi-asserted-by":"crossref","unstructured":"Norman Fenton; Martin Neil, Risk Assessment and Decision Analysis with Bayesian Networks. 1 ed. 2012, USA: CBC Press. 524.","DOI":"10.1201\/9780367803018"},{"key":"10.1016\/j.vaccine.2021.10.079_b0090","doi-asserted-by":"crossref","unstructured":"Vincenzina Vitale;D\u2019Urso, Pierpaolo, and De Giovanni, Livia, Spatio-temporal Object-Oriented Bayesian Network modelling of the COVID-19 Italian outbreak data. Spatial Statistics, 2021: p. 100529.","DOI":"10.1016\/j.spasta.2021.100529"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.079_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/systems8020021","article-title":"Effectiveness of the Early Response to COVID-19: Data Analysis and Modelling","volume":"8","author":"Bertone","year":"2020","journal-title":"Systems"},{"key":"10.1016\/j.vaccine.2021.10.079_b0100","doi-asserted-by":"crossref","unstructured":"Junyi Wang;Zhai, Xueting, and Luo, Qiuju. How COVID-19 Impacts Chinese Travelers\u2019 Mobility Decision-Making Processes: A Bayesian Network Model. In: Information and Communication Technologies in Tourism 2021. 2021. Cham: Springer International Publishing.","DOI":"10.1007\/978-3-030-65785-7_53"},{"key":"10.1016\/j.vaccine.2021.10.079_b0105","doi-asserted-by":"crossref","unstructured":"Georgina Prodhan, Fenton, Norman, Extending the range of COVID-19 risk factors in a Bayesian network model for personalised risk assessment. medRxiv, 2020: p. 2020.10.20.20215814.","DOI":"10.1101\/2020.10.20.20215814"},{"key":"10.1016\/j.vaccine.2021.10.079_b0110","unstructured":"Lai K, Yanushkevich S. Machine Reasoning to Assess Pandemics Risks: Case of USS Theodore Roosevelt. ArXiv, 2020. abs\/2008.11040."},{"key":"10.1016\/j.vaccine.2021.10.079_b0115","doi-asserted-by":"crossref","unstructured":"Norman E. Fenton, et al., A Bayesian network model for personalised COVID19 risk assessment and contact tracing. medRxiv, 2021: p. 2020.07.15.20154286.","DOI":"10.1101\/2020.07.15.20154286"},{"key":"10.1016\/j.vaccine.2021.10.079_b0120","unstructured":"Scott McLachlan, et al., The fundamental limitations of COVID-19 contact tracing methods and how to resolve them with a Bayesian network approach. 2020."},{"key":"10.1016\/j.vaccine.2021.10.079_b0125","article-title":"Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling","volume":"149","author":"Yue","year":"2021","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2021.10.079_b0130","doi-asserted-by":"crossref","unstructured":"Rachel Butcher and Fenton, Norman, Extending the range of symptoms in a Bayesian Network for the Predictive Diagnosis of COVID-19. medRxiv, 2020: p. 2020.10.22.20217554.","DOI":"10.1101\/2020.10.22.20217554"},{"key":"10.1016\/j.vaccine.2021.10.079_b0135","unstructured":"Edward Burn, et al., Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countries. medRxiv, 2021: p. 2021.05.12.21257083."},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.079_b0140","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/STROKEAHA.120.030800","article-title":"Incidence and Mortality of Cerebral Venous Thrombosis in a Norwegian Population","volume":"51","author":"Kristoffersen","year":"2020","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.079_b0145","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vaccine.2021.10.079_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2016.02.024","article-title":"Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study","volume":"141","author":"S\u00f8gaard","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.vaccine.2021.10.079_b0155","unstructured":"James B. Bussel; Jean M. Connors; Douglas B. Cines; Cynthia E. Dunbar; Laura C. Michaelis; Lisa Baumann Kreuziger; Agnes Y.Y. Lee; Ingrid Pabinger-Fasching Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia). 2021. https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia."},{"key":"10.1016\/j.vaccine.2021.10.079_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101061","article-title":"Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases","volume":"39","author":"Taquet","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2021.10.079_b0165","unstructured":"Tom Shimabukuro; National Center for Immunization & Respiratory Diseases Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-05-12\/07-COVID-Shimabukuro-508.pdf."},{"key":"10.1016\/j.vaccine.2021.10.079_b0170","unstructured":"NSW Government NSW COVID-19 cases data. 2021. https:\/\/data.nsw.gov.au\/nsw-covid-19-data\/cases."},{"key":"10.1016\/j.vaccine.2021.10.079_b0175","unstructured":"Australian Government Department of Health National Notifiable Diseases Surveillance System public datasets. 2021. https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-pub-datasets.htm."},{"key":"10.1016\/j.vaccine.2021.10.079_b0180","unstructured":"Doherty Institute, Doherty modelling report revised 10th August 2021. 2021, Doherty Institute. p. Table S2.5."},{"key":"10.1016\/j.vaccine.2021.10.079_b0185","unstructured":"Australian Government Department of Health News and Media. 2021. https:\/\/www.health.gov.au\/news?f%5B0%5D=field_date_updated%3A2021."},{"key":"10.1016\/j.vaccine.2021.10.079_b0190","unstructured":"Australian Bureau of Statistics Data downloads - time series spreadsheets. National, state and territory population, 2021. https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/dec-2020#data-download."},{"key":"10.1016\/j.vaccine.2021.10.079_b0195","unstructured":"Australian Government Department of Health COVID-19 vaccination \u2013 Primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine. 2021. https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-primary-care-approach-to-thrombosis-with-thrombocytopenia-syndrome-after-covid-19-astrazeneca-vaccine."},{"key":"10.1016\/j.vaccine.2021.10.079_b0200","doi-asserted-by":"crossref","unstructured":"Vivien Chen; Jennifer L. Curnow; Huyen Tran; Philip Young-Ill Choi, Australian New Zealand approach to diagnosis and management of vaccine induced immune thrombosis and thrombocytopenia. Medical Journal of Australia, 2021.","DOI":"10.5694\/mja2.51229"},{"key":"10.1016\/j.vaccine.2021.10.079_b0205","unstructured":"VITT Communication Committee THANZ Multidisciplinary VITT Guideline for Doctors. 2021. https:\/\/www.thanz.org.au\/news\/vitt-multidisciplinary-guideline-for-doctors."},{"key":"10.1016\/j.vaccine.2021.10.079_b0210","article-title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study","volume":"371","author":"Clift","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.10.079_b0215","unstructured":"Johns Hopkins. COVID-19 Risk Tools. COVID-19 Risk Tooks 2021 [cited 25 September 2021]; Available from: https:\/\/covid19risktools.com:8443\/riskcalculator#mainbody."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.079_b0220","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12911-021-01594-8","article-title":"Impact of an interactive web tool on patients\u2019 intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France","volume":"21","author":"Tran","year":"2021","journal-title":"BMC Med Inf Decis Making"},{"key":"10.1016\/j.vaccine.2021.10.079_b0225","unstructured":"ISARIC4C (Coronavirus Clinical Characterisation Consortium). ISARIC4C Mortality Score. ISARIC4C 2021; Available from: https:\/\/isaric4c.net."},{"key":"10.1016\/j.vaccine.2021.10.079_b0230","unstructured":"National Institute on Ageing. My COVID-19 Visit Risk Calculator. 2021 [cited 25 September 2021]; Available from: https:\/\/covidvisitrisk.com\/riskscore-english.html."},{"key":"10.1016\/j.vaccine.2021.10.079_b0235","unstructured":"The microCOVID Project. microCOVID Project. 2021 [cited 25 September 2021]; Available from: https:\/\/www.microcovid.org\/about."},{"key":"10.1016\/j.vaccine.2021.10.079_b0240","unstructured":"Lifespan; Warren Alpert Medical School of Brown University. MyCOVIDRisk. 2021 [cited 25 September 2021]; Available from: https:\/\/mycovidrisk.app."},{"key":"10.1016\/j.vaccine.2021.10.079_bib241","article-title":"Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine","author":"Mayfield","year":"2021","journal-title":"medRxiv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:05:55Z","timestamp":1759403155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21014286"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.079","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.30.21264337","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}